Recommencement of ZIRCON Phase III Trial Recruitment in Europe

Melbourne (Australia) – 18th June 2020. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the Company’s ZIRCON phase III trial of TLX250-CDx (89Zr-girentuximab)1 has recommenced patient recruitment in Europe, following a pause to clinical trial activity as a result of the COVID-19 pandemic.2

Patient recruitment to the ZIRCON trial has recommenced at clinical sites in France with the dosing of two patients with TLX250-CDx this week at Centre Hospitalier Universitaire (CHU) de Nantes (Nantes, France). Clinical sites in Belgium and the Netherlands have also been reactivated, with patient recruitment expected to resume in the next two weeks. Telix expects clinical trial sites in Australia, Canada, Turkey and USA to follow between now and September, subject to conditions remaining stable.

Telix CEO, Dr Christian Behrenbruch stated, “We are relieved to be restarting patient recruitment into the ZIRCON study and gratefully acknowledge the patience and dedication of our investigators and their clinical staff during this necessary hiatus. Although we had stopped patient enrolment, we had not paused recruitment and we see an encouraging patient backlog to regain momentum.”

About the ZIRCON Study

ZIRCON (Zirconium Imaging in Renal Cancer Oncology, NCT03849118) is an international multi-centre Phase III study at 33 sites in Europe, Australia, Turkey, Canada and the United States (subject to regulatory approval in the various jurisdictions). ZIRCON is a prospective imaging trial in approximately 250 renal cancer patients undergoing kidney surgery, to determine the sensitivity and specificity of TLX250-CDx PET imaging to detect clear cell renal cell cancer (ccRCC) in comparison with histologic “standard of truth” determined from surgical resection specimens.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne with international operations in Belgium, Japan and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact
Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations
Dr David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

1 For the imaging of renal cancer with positron emission tomography (PET).
2 ASX release 22nd April 2020.